Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 81

1.

Design and synthesis of isoxazoline derivatives as factor Xa inhibitors. 1.

Quan ML, Liauw AY, Ellis CD, Pruitt JR, Carini DJ, Bostrom LL, Huang PP, Harrison K, Knabb RM, Thoolen MJ, Wong PC, Wexler RR.

J Med Chem. 1999 Jul 29;42(15):2752-9.

PMID:
10425086
2.

Orally active isoxazoline glycoprotein IIb/IIIa antagonists with extended duration of action.

Olson RE, Sielecki TM, Wityak J, Pinto DJ, Batt DG, Frietze WE, Liu J, Tobin AE, Orwat MJ, Di Meo SV, Houghton GC, Lalka GK, Mousa SA, Racanelli AL, Hausner EA, Kapil RP, Rabel SR, Thoolen MJ, Reilly TM, Anderson PS, Wexler RR.

J Med Chem. 1999 Apr 8;42(7):1178-92.

PMID:
10197962
3.

Antiplatelet efficacy of XV459, a novel nonpeptide platelet GPIIb/IIIa antagonist: comparative platelet binding profiles with c7E3.

Mousa SA, Bozarth JM, Lorelli W, Forsythe MS, Thoolen MJ, Slee AM, Reilly TM, Friedman PA.

J Pharmacol Exp Ther. 1998 Sep;286(3):1277-84.

PMID:
9732389
4.

Oral antiplatelet efficacy and specificity of a novel nonpeptide platelet GPIIb/IIIa receptor antagonist, DMP 802.

Mousa SA, Olson RE, Bozarth JM, Lorelli W, Forsythe MS, Racanelli A, Gibbs S, Schlingman K, Bozarth T, Kapil R, Wityak J, Sielecki TM, Wexler RR, Thoolen MJ, Slee A, Reilly TM, Anderson PS, Friedman PA.

J Cardiovasc Pharmacol. 1998 Aug;32(2):169-76.

PMID:
9700976
5.

Discovery of an orally active series of isoxazoline glycoprotein IIb/IIIa antagonists.

Xue CB, Wityak J, Sielecki TM, Pinto DJ, Batt DG, Cain GA, Sworin M, Rockwell AL, Roderick JJ, Wang S, Orwat MJ, Frietze WE, Bostrom LL, Liu J, Higley CA, Rankin FW, Tobin AE, Emmett G, Lalka GK, Sze JY, Di Meo SV, Mousa SA, Thoolen MJ, Racanelli AL, Olson RE, et al.

J Med Chem. 1997 Jun 20;40(13):2064-84.

PMID:
9207948
6.

Novel nonpeptide antiplatelet glycoprotein IIb/IIIa receptor antagonist, DMP754: receptor binding affinity and specificity.

Mousa SA, Forsythe M, Lorelli W, Bozarth J, Xue CB, Wityak J, Sielecki TM, Olson RE, DeGrado W, Kapil R, Hussain M, Wexler R, Thoolen MJ, Reilly TM.

Coron Artery Dis. 1996 Oct;7(10):767-74.

PMID:
8970768
7.

A monoclonal antibody that recognizes the GPIIb/IIIa antagonist DMP 728. Reversal of the effects of DMP 728 on platelet aggregation and bleeding time in the dog.

Reilly TM, Mousa SA, Racanelli AL, Thoolen MJ, Flint SK, Bozarth JM, Mu DX, Walton HL.

Arterioscler Thromb Vasc Biol. 1995 Dec;15(12):2195-9.

PMID:
7489242
8.

Preservation of regional and global left ventricular function by intracoronary infusion with oxygenated fluorocarbon emulsion Therox in dogs.

Thoolen MJ, Rasbach DE, Shaw JH, Raynolds S, Timmermans PB.

Biomater Artif Cells Immobilization Biotechnol. 1993;21(1):53-62.

PMID:
8461436
9.

Antiplatelet efficacy and specificity of DMP728, a novel platelet GPIIb/IIIa receptor antagonist.

Mousa SA, Bozarth JM, Forsythe MS, Lorelli W, Thoolen MJ, Ramachandran N, Jackson S, De Grado W, Reilly TM.

Cardiology. 1993;83(5-6):374-82.

PMID:
7509257
10.
11.

Persistent cardioprotection by azapropazone in a canine model of coronary artery thrombosis and thrombolysis.

Knabb RM, Rasbach DE, Leamy AW, Fernando DP, Mackin WM, Boswell GA, Timmermans PB, Thoolen MJ.

J Cardiovasc Pharmacol. 1991 Mar;17(3):390-6.

PMID:
1711599
12.

Early scintigraphic detection of experimental myocardial infarction in dogs with technetium-99m-glucaric acid.

Orlandi C, Crane PD, Edwards DS, Platts SH, Bernard L, Lazewatsky J, Thoolen MJ.

J Nucl Med. 1991 Feb;32(2):263-8.

13.
14.

Monoclonal antibodies directed against basic fibroblast growth factor which inhibit its biological activity in vitro and in vivo.

Reilly TM, Taylor DS, Herblin WF, Thoolen MJ, Chiu AT, Watson DW, Timmermans PB.

Biochem Biophys Res Commun. 1989 Oct 31;164(2):736-43.

PMID:
2479375
15.

Myocardial cytoprotective efficacy of azapropazone in a canine heart model of regional ischemia and reperfusion.

Mousa SA, Cooney JM, Thoolen MJ, Timmermans PB.

J Cardiovasc Pharmacol. 1989 Oct;14(4):542-8.

PMID:
2478767
16.

Nonpeptide angiotensin II receptor antagonists. III. Structure-function studies.

Chiu AT, Duncia JV, McCall DE, Wong PC, Price WA Jr, Thoolen MJ, Carini DJ, Johnson AL, Timmermans PB.

J Pharmacol Exp Ther. 1989 Sep;250(3):867-74.

PMID:
2778716
17.

Nonpeptide angiotensin II receptor antagonists. IV. EXP6155 and EXP6803.

Wong PC, Price WA Jr, Chiu AT, Thoolen MJ, Duncia JV, Johnson AL, Timmermans PB.

Hypertension. 1989 May;13(5):489-97.

PMID:
2656519
18.

Non-peptide angiotensin II receptor antagonists. II. Pharmacology of S-8308.

Chiu AT, Carini DJ, Johnson AL, McCall DE, Price WA, Thoolen MJ, Wong PC, Taber RI, Timmermans PB.

Eur J Pharmacol. 1988 Nov 15;157(1):13-21.

PMID:
3234494
19.

Nonpeptide angiotensin II receptor antagonists. I. Pharmacological characterization of 2-n-butyl-4-chloro-1-(2-chlorobenzyl)imidazole-5-acetic acid, sodium salt (S-8307).

Wong PC, Chiu AT, Price WA, Thoolen MJ, Carini DJ, Johnson AL, Taber RI, Timmermans PB.

J Pharmacol Exp Ther. 1988 Oct;247(1):1-7.

PMID:
3171969
20.
21.

Effect of azapropazone and allopurinol on myocardial infarct size in rats.

Montor SG, Thoolen MJ, Mackin WM, Timmermans PB.

Eur J Pharmacol. 1987 Aug 11;140(2):203-7.

PMID:
3666017
23.

Calcium handling in vasoconstriction to stimulation of alpha 1- and alpha 2-adrenoceptors.

Timmermans PB, Chiu AT, Thoolen MJ.

Can J Physiol Pharmacol. 1987 Aug;65(8):1649-57. Review.

PMID:
2891423
24.

Autoreceptors in the central nervous system.

Timmermans PB, Thoolen MJ.

Med Res Rev. 1987 Jul-Sep;7(3):307-32. Review. No abstract available.

PMID:
3041133
25.
26.

Ca++ utilization in the constriction of rat aorta to full and partial alpha-1 adrenoceptor agonists.

Chiu AT, McCall DE, Thoolen MJ, Timmermans PB.

J Pharmacol Exp Ther. 1986 Jul;238(1):224-31.

PMID:
2873236
27.
28.

Inhibitory effect of calcium antagonist drugs on vasoconstriction induced by vascular alpha 2-adrenoceptor stimulation.

van Zwieten PA, Timmermans PB, Thoolen MJ, Wilffert B, De Jonge A.

Am J Cardiol. 1986 Feb 26;57(7):11D-15D. Review.

PMID:
2869674
29.

Inhibitory effect of alpha-1 adrenoceptor stimulation on cardiac sympathetic neurotransmission in pithed normotensive rats.

de Jonge A, van den Berg G, Qian JQ, Wilffert B, Thoolen MJ, Timmermans PB, van Zwieten PA.

J Pharmacol Exp Ther. 1986 Feb;236(2):500-4.

PMID:
2868121
30.

Central and peripheral effects of S 3341 [(N-dicyclopropylmethyl)-amino-2-oxazoline] in animal models.

van Zwieten PA, Thoolen MJ, Jonkman FA, Wilffert B, de Jonge A, Timmermans PB.

Arch Int Pharmacodyn Ther. 1986 Jan;279(1):130-49.

PMID:
2870686
31.

Subclassification of muscarinic receptors in the heart, urinary bladder and sympathetic ganglia in the pithed rat. Selectivity of some classical agonists.

van Charldorp KJ, de Jonge A, Thoolen MJ, van Zwieten PA.

Naunyn Schmiedebergs Arch Pharmacol. 1985 Dec;331(4):301-6.

PMID:
4094621
32.
33.

Deviating central hypotensive activity of urapidil in the cat.

van Zwieten PA, Mathy MJ, Thoolen MJ.

J Pharm Pharmacol. 1985 Nov;37(11):810-1.

PMID:
2867163
34.

Cardiovascular effects and interaction with adrenoceptors of urapidil.

van Zwieten PA, de Jonge A, Wilffert B, Timmermans PB, Beckeringh JJ, Thoolen MJ.

Arch Int Pharmacodyn Ther. 1985 Aug;276(2):180-201.

PMID:
4051641
35.

Location of the mechanism of the clonidine withdrawal tachycardia in rats.

Jonkman FA, Man PW, Thoolen MJ, van Zwieten PA.

J Pharm Pharmacol. 1985 Aug;37(8):580-2.

PMID:
2864424
36.

Differential selectivities of RU 24969 and 8-OH-DPAT for the purported 5-HT1A and 5-HT1B binding sites. Correlation between 5-HT1A affinity and hypotensive activity.

Doods HN, Kalkman HO, De Jonge A, Thoolen MJ, Wilffert B, Timmermans PB, Van Zwieten PA.

Eur J Pharmacol. 1985 Jun 19;112(3):363-70.

PMID:
3160596
37.
38.

Calcium utilization in the vasoconstriction to enantiomers of SK&F 89748-A.

Matthews WD, Macia RA, Beckeringh JJ, DeMarinis RM, de Jonge A, Thoolen MJ, Wilffert B, Timmermans PB, van Zwieten PA.

J Pharmacol Exp Ther. 1985 Feb;232(2):330-6.

PMID:
2857195
39.

Interference of enantiomers of lofexidine with alpha-adrenoceptors.

Wilffert B, Mathy MJ, Batink HD, de Jonge A, Thoolen MJ, Prop G, Graf E, Timmermans PB, van Zwieten PA.

Arch Int Pharmacodyn Ther. 1985 Jan;273(1):18-32.

PMID:
2988468
40.

Functional consequences of contrasting properties of alpha 1/alpha 2 systems.

Timmermans PB, Thoolen MJ, De Jonge A, Wilffert B, Van Zwieten PA.

Clin Sci (Lond). 1985;68 Suppl 10:93s-97s. No abstract available.

PMID:
2857626
41.

Influence of Bay k 8644 on pressor effects of B-HT 920 and cirazoline in pithed cats.

Wilffert B, Mathy MJ, de Jonge A, Thoolen MJ, Timmermans PB, van Zwieten PA.

J Cardiovasc Pharmacol. 1985 Jan-Feb;7(1):26-9.

PMID:
2580146
42.

Calcium dependency of vasoconstriction mediated by alpha 1- and alpha 2-adrenoceptors.

van Zwieten PA, Timmermans PB, Thoolen MJ, Wilffert B, de Jonge A.

J Cardiovasc Pharmacol. 1985;7 Suppl 6:S113-20.

PMID:
2414571
43.

Affinity of WY 26703 for central and peripheral alpha 1- and alpha 2-adrenoreceptors in the rat; comparison with yohimbine.

Korstanje C, Doods HN, De Jonge A, Thoolen MJ, Wilffert B, Timmermans PB, Van Zwieten PA.

J Auton Pharmacol. 1984 Dec;4(4):287-93.

PMID:
6099362
44.

Effect of chronic elevation of plasma calcium concentration by PTH or vitamin D3 on blood pressure and hypotensive activity of nifedipine in rats.

Jonkman FA, Thoolen MJ, Wilffert B, de Jonge A, Timmermans PB, van Zwieten PA.

Pflugers Arch. 1984 Dec;402(4):341-4.

PMID:
6097872
45.

Invariable susceptibility to blockade by nifedipine of vasoconstriction to various alpha 2-adrenoceptor agonists in pithed rats.

Timmermans PB, Mathy MJ, Thoolen MJ, de Jonge A, Wilffert B, van Zwieten PA.

J Pharm Pharmacol. 1984 Nov;36(11):772-5.

PMID:
6150985
46.

Effect of pithing on the postjunctional sympatho-inhibitory action of captopril in cats.

de Jonge A, Davidesko D, Mathy MJ, Thoolen MJ, Wilffert B, van Brummelen P, Timmermans PB, van Zwieten PA.

Naunyn Schmiedebergs Arch Pharmacol. 1984 Nov;328(1):30-2.

PMID:
6096726
47.

Calcium influx-dependent and -independent alpha 1-adrenoceptor-mediated processes of vasoconstriction in vivo do not operate via different alpha 1-adrenoceptor subtypes.

Korstanje C, Wilffert B, de Jonge A, Thoolen MJ, Timmermans PB, van Zwieten PA.

J Cardiovasc Pharmacol. 1984 Nov-Dec;6(6):1102-8.

PMID:
6084766
48.

Interactions between the putative calcium entry promotor Bay k 8644 and pressor responses produced by alpha 1- and alpha 2-adrenoceptor agonists in the pithed normotensive rat.

Wilffert B, van Heiningen PN, Mathy MJ, de Jonge A, Thoolen MJ, Timmermans PB, van Zwieten PA.

Naunyn Schmiedebergs Arch Pharmacol. 1984 Nov;328(1):76-82.

PMID:
6083459
49.

Lack of effect of D600 on alpha 1-adrenoceptor-mediated contractions of rat isolated anococcygeus muscle.

Vila E, Thoolen MJ, Beckeringh JJ, Timmermans PB, Van Zwieten PA.

Eur J Pharmacol. 1984 Oct 30;106(1):97-105.

PMID:
6152215
50.

Heterogeneity of the interaction between alpha 1- and alpha 2-adrenoceptor agonists with their respective receptors in the vascular system of the pithed rat.

Wilffert B, De Jonge A, Thoolen MJ, Timmermans PB, Van Zwieten PA.

Eur J Pharmacol. 1984 Oct 1;105(1-2):121-7.

PMID:
6149141

Supplemental Content

Loading ...
Support Center